pathologic testing and/or by Aspergillus-specific serologic testing (serum Aspergillus galactomannan antigen index [GMI] ). Despite the availability of effective drugs, the burden of invasive aspergillosis remains significant [1] . Attempts at improving the prognosis of invasive aspergillosis have relied on the early application of more sensitive diagnostic tests, such as chest computed tomography (CT) [2] and serodiagnosis with serial GMI [3] and/or 1-3-b-d-glucan (BDG) [4] , and the evaluation of novel antifungal strategies in randomized clinical trials [5] .
Because the lack of standard diagnostic criteria for invasive aspergillosis constituted a major hurdle for the conduct of randomized clinical trials, the European Organization for Research and Treatment of Cancer (EORTC) and the Mycosis Study Group (MSG) developed the EORTC-MSG consensus definitions for the diagnosis of invasive aspergillosis [6, 7] . These definitions require the presence of host factors and clinical, radiologic, and mycologic criteria, including culture and serodiagnosis (serum GMI or BDG). By making it possible to conduct randomized clinical trials worldwide, these definitions represented a major advance in the field. However, their diagnostic performance is low (25%-50%), compared with the gold standard of autopsy examination [8] [9] [10] [11] . This carries important implications for the conduct of randomized clinical trials of novel therapies. Several factors explain the limited performance of these expert-derived diagnostic criteria.
The first factor is a lack of prospective validation. The second factor is skewing toward patients with advanced disease. These definitions were derived from older publications (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) [12] , before the availability of serum GMI [3] and more effective therapies [5] , and were more representative of patients with advanced disease. The third factor is poor test attributes. The pulmonary CT findings of the patients with EORTC-MSGproven or -probable invasive aspergillosis are given a significant diagnostic weight despite the fact that they are nonspecific [13] , observer dependent [5] , not easily quantifiable, and transient, such as the halo sign [2] . They may even be misleading; indeed, worsening findings may represent an immune reconstitution and inflammatory syndrome in a patient whose invasive aspergillosis is resolving [14] , and the air crescent sign and cavitary lesions may be seen with responding infection [15] . Furthermore, the radiologic findings at extrapulmonary sites are poorly defined and cannot be relied on to suggest invasive aspergillosis [7] . Unlike CT imaging, GMI serodiagnosis fulfills all criteria as a surrogate marker for the diagnosis and outcome evaluation of invasive aspergillosis [16] , with high test performance in patients with hematologic malignant neoplasms [17] and very strong correlation with findings at autopsy examination [18] . Serial GMI monitoring has been shown to significantly shorten the time to diagnosis [17] and timely preemptive antifungal therapy [19] . This, in turn, is thought to positively alter the disease and slow the development of the more overt manifestations that are required by the EORTC-MSG invasive aspergillosis. Fourth, the EORTC-MSG invasive aspergillosis criteria have been derived from patients with profound and prolonged neutropenia and may not apply to those with severe T cell immunodeficiency, such as solid organ or allogeneic hematopoietic stem cell transplant (HCT) recipients, patients with chronic hematologic malignant neoplasms, and others [20, 21] . These patients may present with more inconspicuous images, including ill-defined consolidations, ground-glass attenuation, small nodules (!1 cm), and other findings [20, 22] , none of which qualifies as a diagnostic criterion in the EORTC-MSG invasive aspergillosis [7] .
Because of the expanding population at risk, the major clinical consequences of invasive aspergillosis, and the limited number of effective therapies, it is crucial that enrollment in randomized clinical trials of potentially effective therapies of invasive aspergillosis be facilitated for these trials to be performed quickly, efficiently, and at minimal costs [16] .
The objective of this study was to identify criteria that would improve on the 25%-50% diagnostic sensitivity [8] [9] [10] [11] of the EORTC-MSG invasive aspergillosis definitions. We hypothesized that patients at risk for invasive aspergillosis who fulfill all criteria for EORTC-MSG invasive aspergillosis (plus a requirement for a positive GMI test result), but who do not exhibit the prespecified radiologic criteria for EORTC-MSG invasive aspergillosis, in fact have invasive aspergillosis. In this report of 125 consecutive cases of invasive aspergillosis in 121 high-risk patients cared for in a myeloma center with frequent serial serologic testing, we show that host factors, clinical characteristics, mycologic criteria, and survival at 4, 6, and 12 weeks after diagnosis in 42 such patients (referred to as probable invasive aspergillosis without prespecified radiologic criteria) are almost identical to those of 83 patients with proven or probable EORTC-MSG invasive aspergillosis.
PATIENTS AND METHODS
This is a retrospective evaluation of a cohort of 125 consecutive episodes of invasive aspergillosis in 121 cancer patients who were prospectively followed up by one of us (E.A.) and cared for at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, from January 2003 through December 2009. The study was approved by the Institutional Review Board. Subjects consisted of patients with cancer at risk for invasive aspergillosis because of immunosuppressive therapies. All patients were managed according to the predefined standards of care at the Myeloma Institute for Research and Therapy. For the purpose of the present study, 2 of the authors (S.A.N. and M.N., both physicians with expertise in invasive aspergillosis) reviewed patients' medical records, including all images (chest radiographs, CTs, and positron emission tomograms).
Cases were classified as proven or probable according to the revised EORTC-MSG criteria [7] (control group) or as probable invasive aspergillosis without prespecified radiologic criteria (study group). This latter category fulfilled the same criteria as the former (plus a required positive serum GMI test result), except that the abnormal pulmonary infiltrates findings did not fulfill the 3 following EORTC-MSG radiologic criteria: dense, well-circumscribed lesions, air crescent sign, or cavity. A diagnosis of sinusitis was made in the presence of clinical findings (dry cough, postnasal dripping, nasal obstruction, nasal discharge, or sinus pain) and CT images compatible with sinusitis. All findings were temporarily related to the period at risk, and alternative causes were excluded. Serum GMI testing was obtained serially (typically 3 times a week) after the start of antineoplastic therapy and performed according to the manufacturer's instructions (Platelia Aspergillus EIA; Bio-Rad). A positive GMI test result was defined as an optical density index of у0.5. Beginning August 2008, monitoring with serum BDG (Fungitell assay; Associates of Cape Cod) was performed 3 times a week, and results у80 pg/mL were considered to be positive. Patients with false-positive GMI and/or BDG results were excluded.
Study variables were examined at 2 time points, immediately before the initiation of the chemotherapy regimen after which invasive aspergillosis was diagnosed and within 12 weeks after the diagnosis of invasive aspergillosis. The date of the first positive GMI test result was considered to be the date of diagnosis of invasive aspergillosis.
Variables before invasive aspergillosis included demographic characteristics, underlying cancer and its status (remission or active disease), type of treatment (chemotherapy, autologous, or allogeneic HCT), number of prior HCTs, cumulative corticosteroid dose (in milligrams equivalent to prednisone), receipt of other immunosuppressive agents, white blood cell count, absolute lymphocyte and platelet counts, serum bilirubin and creatinine levels, cytomegalovirus serostatus, serum levels of normal (uninvolved) immunoglobulins (for patients with multiple myeloma), and absolute CD4 cell count within 1 month before the diagnosis of invasive aspergillosis.
Variables after invasive aspergillosis consisted of the clinical and radiologic manifestations of invasive aspergillosis, depth and duration of neutropenia, absolute neutrophil count at diagnosis of invasive aspergillosis, cytomegalovirus reactivation within 60 days after diagnosis and concomitant respiratory viral infections, several GMI variables (number of positive results, area under the GMI curve, peak value, time to peak value, and time to normalization), antifungal therapy, and outcome (survival at 4, 6, and 12 weeks). The dynamics of BDG were also examined.
Antifungal prophylaxis consisted of fluconazole, 200 mg orally daily, during neutropenia, which was defined as an absolute neutrophil count !500 neutrophils/mm 3 and was considered to be severe when the neutrophil count was !100 neutrophils/mm 3 . Hematopoeitic recovery referred to 3 consecutive absolute neutrophil counts у500 neutrophils/mm 3 . Chemotherapy was considered to be myelosuppressive if it resulted in neutropenia and myeloablative if it required autologous or allogeneic HCT. Radiologic images were reported according to published recommendations [23] .
Mold-active antifungal therapy (voriconazole or liposomal amphotericin B [AmBisome]) at standard recommended doses for therapy of invasive aspergillosis was started on first positive serum GMI test result and confirmation of invasive aspergillosis on the basis of host, clinical, and radiologic criteria (typically within 24-48 h). Diagnostic work-up included CT of sinuses and chest and respiratory samples for fungal stains and cultures. Adjuvant therapy was added as clinically indicated. No attempt was made to provide different care for patients on the basis of their radiologic findings whether specific per EORTC-MSG criteria or not [7, 23] .
The principal objective of this study was to compare the characteristics of cases and controls with host, clinical, radiologic, and mycologic characteristics and survival serving as specific study end points. Categorical data were analyzed using x 2 or Fisher's exact tests as appropriate, and continuous variables were compared using the Wilcoxon test. Survival curves were constructed using the Kaplan-Meier method and compared by the log-rank test, taking into account the date of diagnosis of invasive aspergillosis and the date of death or last follow-up, censored at day 90 after the diagnosis of invasive aspergillosis. Because Aspergillus sinusitis is typically associated with better outcomes than invasive pulmonary aspergillosis, 2 survival analyses were performed; 1 including all patients and 1 in which patients with Aspergillus sinusitis only were excluded.
All analyses were performed using SPSS statistical software, version 15.0 for Windows (SPSS).
was considered to be P ! .05 statistically significant.
RESULTS
During the 7-year study period, 125 episodes of invasive aspergillosis associated with a positive GMI test result were diagnosed in 121 patients. Forty-two episodes were cases (33%), and 83 served as controls (67%). All but 11 patients had multiple myeloma. The baseline characteristics (Table 1) and clinical manifestations (Table 2 ) of cases and controls were comparable except for the higher baseline platelet count, shorter duration of neutropenia, and lower rate of fever among cases. Except for the 3 EORTC-MSG invasive aspergillosis pulmonary lesions (as predefined), the radiologic findings of both groups were also comparable, consisting mainly of consolidations that were not well circumscribed, ground-glass infiltrates, and pleural effusions (Table 2) . Twenty-six of 53 cases originally classified as probable invasive aspergillosis without prespecified radiologic criteria underwent repeat imaging at a median of 13.5 days (range, 2-30 days) after their first CT examination, and 11 (42%) were reclassified as controls because of the development of dense, well-circumscribed consolidations and/or macronodules. Single-organ involvement (lungs or sinuses) was more frequent among cases than controls (38 episodes [90%] vs 59 episodes [71%];
), probably because of a higher P p .007 incidence of sinusitis among the former group (7 episodes [17%] vs 2 episodes [2%]).
No differences between cases and controls (Table 2) were observed in the mycologic criteria, with fungal cultures yielding Aspergillus species in 29% and 19%, respectively. The GMI variables also did not significantly differ between the 2 groups, including the proportion of patients with GMI as single mycologic criterion, time to first positive result, peak value, time to peak value, time to normalization, and area under the GMI curve. Similar findings were observed when the BDG characteristics were examined ( Table 2 ). The serum BDG test result was negative in only 3 (10%) of the 29 episodes in which it was performed, including 2 controls (59 and 62 pg/mL) and 1 case (78 pg/mL). The primary treatment for invasive aspergillosis was voriconazole in 62% of patients, followed by liposomal amphotericin B. The median duration of treatment was 22 days (range, 2-82 days). Treatment practices did not differ between the 2 study groups, except for a higher use of granulocyte-macrophage colony-stimulating factor among controls. The survival of cases and controls was also comparable (Figure 1 ). Among patients with invasive pulmonary aspergillosis, the 90-day cumulative survival was 64% for cases and 52% for controls ( ). There were no differences in survival between pa-P p .27 tients with positive or negative cultures ( ). P p .38
DISCUSSION
Our results indicate that the features of patients with probable invasive aspergillosis without prespecified radiologic criteria are NOTE. Data are no. or proportion (%) of patients, unless otherwise indicated. BDG, serum 1-3-b-d-glucan; GMI, serum Aspergillus galactomannan index; PET/CT, positron emission tomography/computed tomography using fluorodeoxyglucose 18 radiotracer.
a Symptoms of lower respiratory tract infection included the following: for EORTC-MSG controls, cough (31), cough and dyspnea (17) , dyspnea (11), wheezing (1), and chest pain (1); for probable invasive aspergillosis without prespecified radiologic criteria, cough (16), cough and dyspnea (6), dyspnea (4), and hemoptysis (1). b Symptoms of sinusitis included the following: for proven or probable cases, nasal congestion (4) and runny nose (1); for probable invasive aspergillosis without prespecified radiologic criteria, nasal congestion (5). c By definition, cases of probable invasive aspergillosis without prespecified radiologic criteria were those whose chest computed tomography scan did not reveal dense well-circumscribed lesions, air crescent sign, or cavitation. comparable to those with EORTC-MSG invasive aspergillosis. That patients in this new category of invasive aspergillosis have aspergillosis is strengthened by the following 8 points: (1) the reclassification of 11 cases of probable invasive aspergillosis with prespecified radiologic criteria as EORTC-MSG invasive aspergillosis on repeat imaging, suggesting that this category may represent an earlier stage of the infection; (2) the comparable risk factors between cases and controls, including demographic characteristics, underlying disease characteristics (type, duration, and status), antineoplastic therapy (prior and current and receipt of HCT), cumulative corticosteroid doses, baseline absolute CD4 cell counts, serum immunoglobulin levels, and renal and liver function test results (the baseline absolute neutrophil count and the proportion of patients with postchemotherapy neutropenia were also comparable among the 2 groups); (3) the similar clinical manifestations; (4) the comparable radiologic findings in lungs and sinuses (except for the 3 EORTC-MSG invasive aspergillosis images as predefined); (5) the comparable rate of recovery and distribution of Aspergillus species with predominance of Aspergillus fumigatus, Aspergillus niger, and Aspergillus flavus; (6) the almost identical characteristics of serum GMI, including proportion of cases with GMI as a single mycologic criterion, rate of positive test results, time to first positive result, peak value, time to peak value, time to normalization, and area under the GMI curve (this is further supported by the multiple consecutively positive GMI in both groups and the strong correlation between GMI values and outcome, as reported elsewhere for 56 of our patients [24, 25] and in this cohort [data not shown]); (7) the concomitantly positive serum BDG test result, an established marker for invasive fungal infection, which is included in the revised EORTC-MSG invasive aspergillosis definitions [7] ; and (8) the similar rates of survival.
This new category of probable invasive aspergillosis without prespecified radiologic criteria likely represents an earlier stage of the disease, as shown by the shorter duration of neutropenia, the lower propensity for involvement of both sinuses and lungs (vs sinuses only) in these patients, and the reclassification of 11 cases to controls on subsequent imaging. Importantly, these results were observed in a high-risk homogeneous patient population (91% with myeloma) cared for at a single institution who were undergoing standardized antineoplastic therapies and infectious disease management, which included serial serodiagnostic tests with GMI, diagnostic work-up, and antifungal therapies.
Compared with conventional diagnostic tools, serial GMI screening shortens the time to diagnosis by several days before the clinical and radiologic findings that form the basis for the EORTC-MSG invasive aspergillosis criteria [3, 17, 26, 27] . The overt EORTC-MSG features of invasive pulmonary aspergilDownloaded from https://academic.oup.com/cid/article-abstract/51/11/1273/373589 by guest on 21 January 2019 losis, derived from studies published as early as 25 years ago (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) [11] , have probably been altered by the recent application of serodiagnosis-based preemptive treatment with novel, more effective, and better tolerated agents, in a fashion reminiscent of the impact of such a strategy on cytomegalovirus disease, particularly cytomegalovirus pneumonia. Indeed, this condition was frequent (30%-35%) and severe at presentation, with an 87% case-fatality rate [28] . The application of novel preemptive therapy has markedly reduced the incidence of patients who develop overt manifestations and/or die of cytomegalovirus pneumonia [29, 30] . Similarly, the case-fatality rate for invasive pulmonary aspergillosis has progressively decreased from 86% in a review of 1223 cases from 1972 through 1995 [31] to 60% in studies published from 1995 through 1999 [32] and to 40%-43% in more recent reports [33, 34] , including a 33% case-fatality rate at 6 weeks in the present series. This consistent survival benefit coincided with the introduction of serodiagnosis-based preemptive therapy with more effective antifungal agents. That such a strategy was not available at the time of the older reports (1985-1997) on which the EORTC-MSG invasive aspergillosis criteria were based [12] suggests that these criteria may represent more advanced invasive aspergillosis than currently observed, at least at the many centers where prophylaxis and/or serodiagnosis-based preemptive therapy with mold-active antifungal agents are applied, and may therefore not reflect current practices.
One differentiating feature between the 2 groups was the better immune status of patients with serologic testing-supported invasive aspergillosis, as suggested by significantly higher baseline platelet counts, shorter neutropenia, lower propensity for involvement of both sinuses and lungs (vs sinuses only), and a trend for a higher rate of concomitant respiratory viral infections in controls (19% vs 7%;
). The impact of P p .07 these viral infections on the radiologic pattern of invasive aspergillosis should be further evaluated.
A significant limitation of the EORTC-MSG definition of invasive aspergillosis is that nonspecific radiologic findings are given equal weight as Aspergillus-specific mycologic criteria. Indeed, CT findings are nonspecific [13, 35] , not easily quantifiable, observer dependent [5] , transient [15] , or even misleading in the setting of rapid immune reconstitution [25] , and the air crescent and cavitary lesions may represent responding aspergillosis [15] . Because of these significant limitations and because radiologic findings at extrapulmonary sites of invasive aspergillosis are poorly defined, we recommend that the definitions of invasive aspergillosis be revisited. Like with other infections (eg, cytomegalovirus), greater weight should be given to Aspergillus-specific microbiologic criteria, as opposed to nonspecific radiologic findings. In contrast to the limitations of imaging, serodiagnosis with Aspergillus-specific GMI fulfills all criteria as a surrogate marker for both diagnosis and outcome evaluation of invasive aspergillosis [16] .
Our findings have important implications. The addition of serologic test-supported invasive aspergillosis as a new diagnostic criterion will significantly increase the sensitivity of the EORTC-MSG invasive aspergillosis definitions [8] [9] [10] [11] and, therefore, improve our ability to conduct randomized clinical trials of invasive aspergillosis therapies quickly and efficiently [16] .
Our study shares the limitations of retrospective studies and has a low autopsy rate, a trend noted worldwide [8] . However, the case definition of serologic test-supported invasive aspergillosis was prospectively established, and serial GMI and BDG monitoring was part of our predefined standards of care. Future studies should expand our findings to other patient populations at risk for aspergillosis.
We conclude that the host, clinical, radiologic, and mycologic characteristics and outcome of patients with serologic testsupported invasive aspergillosis are similar to those with EORTC-MSG invasive aspergillosis except for the less wellcircumscribed consolidations. Serologic test-supported invasive aspergillosis likely represents an earlier stage of the disease and should therefore be considered probable invasive aspergillosis. Enrolling patients with serologic test-supported invasive aspergillosis will increase the pool of eligible study participants, a critical step toward improving the speed, efficiency, and costs of randomized clinical trials of novel therapies.
